UK-369,003

DRUG5 trials

Sponsors

Pfizer

Conditions

ImpotenceProstatic HyperplasiaPulmonary Disease, Chronic ObstructiveUrinary Bladder, Overactive

Phase 1

A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

CompletedNCT00163098

PfizerPulmonary Disease, Chronic Obstructive

Start: 2004-12-31End: 2005-12-31Target: 136Updated: 2006-10-13

Phase 2

Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

CompletedNCT00141349

PfizerImpotence

Start: 2005-02-28End: 2005-08-31Target: 300Updated: 2006-07-25

Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

CompletedNCT00408954

PfizerProstatic Hyperplasia

Start: 2007-03-31End: 2008-06-30Updated: 2010-11-23

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

CompletedNCT00457457

PfizerProstatic Hyperplasia

Start: 2007-05-31End: 2008-04-30Updated: 2018-12-19

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

CompletedNCT00479505

PfizerUrinary Bladder, Overactive

Start: 2007-06-30End: 2008-06-30Target: 275Updated: 2011-03-23